RxSight (RXST) Q2 Loss Beats Estimates

RxSight reported mixed Q2 2025 results, with Non-GAAP loss per share of $(0.08) significantly outperforming estimates, driven by a GAAP gross margin improvement to 74.9% due to a favorable shift towards high-margin Light Adjustable Lens (LAL) consumable sales, which grew 13% year-over-year. However, total GAAP revenue declined 4% year-over-year to $33.6 million, missing analyst expectations, primarily due to a 49% drop in Light Delivery Device (LDD) system sales. Despite the gross margin expansion, GAAP net loss widened to $(11.8 million) as operating expenses surged 20%, highlighting the challenge of balancing growth investments with capital equipment sales volatility, though full-year revenue guidance remains unchanged.

Analysis

RxSight's Q2 2025 results present a bifurcated picture, characterized by improving unit economics but weakening top-line growth. The company reported a significant non-GAAP EPS beat, with a loss of $(0.08) versus a $(0.25) consensus estimate, driven primarily by a substantial expansion in GAAP gross margin to 74.9% from 69.5% a year prior. This margin improvement was a direct result of a favorable sales mix shift towards high-margin, recurring Light Adjustable Lens (LAL) consumables, which saw procedure volume grow 13% year-over-year. However, this positive was overshadowed by a 4% decline in total GAAP revenue to $33.6 million, missing estimates, and caused by a sharp 49% year-over-year drop in lower-margin Light Delivery Device (LDD) capital equipment sales. This slowdown in new system placements is a key concern, though partially offset by a 34% YoY growth in the total installed LDD base to 1,084 units, which supports future LAL sales. The company's path to profitability remains challenged, as a 20% increase in operating expenses to $39.2 million drove the GAAP net loss to widen to $11.8 million from $6.1 million in Q2 2024. Management reiterated its full-year guidance, which implies a revenue decline of 7% to 14% for FY2025, signaling persistent headwinds despite a strong cash position of $227.5 million.

Key Decisions for Investors

• Investors should weigh the near-term headwind from a 49% drop in capital equipment sales against the long-term potential indicated by the 13% growth in recurring, high-margin lens procedures.
• Carefully monitor the growth rate of the installed Light Delivery Device base, which expanded 34% year-over-year, as this is the primary leading indicator for future high-margin consumable revenue.
• Scrutinize the trajectory of operating expenses, which rose 20%, as the company's ability to manage costs relative to gross profit will be critical to reversing the trend of widening GAAP net losses.
• Given the reiterated full-year guidance projecting a revenue decline of 7% to 14%, investors should consider if the current valuation adequately reflects these anticipated near-term challenges versus the long-term adoption story.